Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RA, Polman CH.
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.
Neurology. 2001 Sep 25;57(6):1129-31.
Kalkers NF, Bergers E, Castelijns JA, van Walderveen MA, Bot JC, Ader HJ, Polman CH, Barkhof F. Optimizing the association between disability and biological markers in MS.
Neurology. 2001 Oct 9;57(7):1253-8.
Sorman MP, Bruzzi P, Rovaris M, Barkhof F, Comi G, Miller DH, Cutter GR, Filipp M. Related
Modelling new enhancing MRI lesion counts in multiple sclerosis. Mult Scler. 2001 Oct;7(5):298-304.
Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; European Study Group on Interferon Beta-1b in Secondary Progressive MS.
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Neurology. 2001 Dec 26;57(12):2191-7.
Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, Hahn D, Rolland Y, Salonen O, Pozzilli C, Polman CH, Thompson AJ, Kappos L, Miller DH; European Study Group on Interferon beta-1b in Secondary Progressive MS. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Neurology. 2001 Dec 26;57(12):2185-90.
Barkhof F, Scheltens P.
Imaging of white matter lesions. Cerebrovasc Dis. 2002;13 Suppl 2:21-30. Review.
van der Meijs AH, Tan IL, Barkhof F.
Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis.
Mult Scler. 2002 Feb;8(1):64-7.
McFarland HF, Barkhof F, Antel J, Miller DH.
The role of MRI as a surrogate outcome measure in multiple sclerosis.
Mult Scler. 2002 Feb;8(1):40-51. Review.
Tan IL, Pouwels PJ, van Schijndel RA, Ader HJ, Manoliu RA, Barkhof F.
Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis patients: initial experience.
Eur Radiol. 2002 Mar;12(3):559-67. Epub 2001 Nov 27.
Bot JC, Barkhof F, Lycklama a Nijeholt G, van Schaardenburg D, Voskuyl AE, Ader HJ, Pijnenburg JA, Polman CH, Uitdehaag BM, Vermeulen EG, Castelijns JA.
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology. 2002 Apr;223(1):46-56.
Killestein J, Olsson T, Wallstrom E, Svenningsson A, Khademi M, Blumhardt LD, Fagius J, Hillert J, Landtblom AM, Edenius C, Arfors L, Barkhof F, Polman CH. Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.
Ann Neurol. 2002 Apr;51(4):467-74.
Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Thompson AJ.
Two-year follow-up study of primary and transitional progressive multiple sclerosis.
Mult Scler. 2002 Apr;8(2):108-14.
Killestein J, Rep MH, Meilof JF, Ader HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH.
Seasonal variation in immune measurements and MRI markers of disease activity in MS.
Neurology. 2002 Apr 9;58(7):1077-80.
Tan IL, van Schijndel RA, van Walderveen MA, Quist M, Bos R, Pouwels PJ, Desmedt P, Ader HJ, Barkhof F. Magnetic resonance image registration in multiple sclerosis: comparison with repositioning error and observer-based variability.
J Magn Reson Imaging. 2002 May;15(5):505-10.
Bergers E, Bot JC, van der Valk P, Castelijns JA, Lycklama a Nijeholt GJ, Kamphorst W, Polman CH, Blezer EL, Nicolay K, Ravid R, Barkhof F.
Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology.
Ann Neurol. 2002 May;51(5):652-6.
Tan IL, van Schijndel RA, Fazekas F, Filippi M, Freitag P, Miller DH, Yousry TA, Pouwels PJ, Ader HJ, Barkhof F. Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study.
J Neurol. 2002 Jun;249(6):767-73.
Barkhof F.
The clinico-radiological paradox in multiple sclerosis revisited.
Curr Opin Neurol. 2002 Jun;15(3):239-45. Review.
van Veen T, Kalkers NF, Crusius JB, van Winsen L, Barkhof F, Jongen PJ, Pena AS, Polman CH, Uitdehaag BM. The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
J Neuroimmunol. 2002 Jul;128(1-2):95-100.
Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ.
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
Brain. 2002 Aug;125(Pt 8):1676-95. Review.
Tan IL, van Schijndel RA, Pouwels PJ, Ader HJ, Barkhof F.
Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions. AJR Am J Roentgenol. 2002 Sep;179(3):777-82.
Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F.
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol. 2002 Oct;59(10):1572-6.
Hoogervorst EL, Polman CH, Barkhof F.
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler. 2002 Oct;8(5):415-9.
Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F.
Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
Mult Scler. 2002 Oct;8(5):410-4.
Barkhof F.
Whole-brain T1-relaxation time measurements in multiple sclerosis.
J Neurol. 2002 Oct;249(10):1451-2.
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH.
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002 Dec;8(6):532-3.
Bergers E, Bot JC, De Groot CJ, Polman CH, Lycklama a Nijeholt GJ, Castelijns JA, van der Valk P, Barkhof F. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions.
Neurology. 2002 Dec 10;59(11):1766-71.
Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.
J Neuroimmunol. 2002 Dec;133(1-2):225-32.
Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G, Polman CH, Uitdehaag BM. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Neurology. 2003 Jan 28;60(2):219-23.
Lycklama a Nijeholt G, Barkhof F.
Differences between subgroups of MS: MRI findings and correlation with histopathology.
J Neurol Sci. 2003 Feb 15;206(2):173-4. Review.
Inglese M, van Waesberghe JH, Rovaris M, Beckmann K, Barkhof F, Hahn D, Kappos L, Miller DH, Polman C, Pozzilli C, Thompson AJ, Yousry TA, Wagner K, Comi G, Filippi M. Related Articles,
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
Neurology. 2003 Mar 11;60(5):853-60.
Horsfield MA, Barker GJ, Barkhof F, Miller DH, Thompson AJ, Filippi M.
Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging. 2003 Apr;17(4):389-97.
Lopatinskaya L, van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L.
The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J Neuroimmunol. 2003 May;138(1-2):123-31.
Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernandez O, Seeldrayers P, Sorensen P, Margrie S, Rovaris M, Comi G, Filippi M; Early Treatment of Multiple Sclerosis Study Group. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Ann Neurol. 2003 Jun;53(6):718-24.
van Veen T, Crusius JB, van Winsen L, Xia B, Barkhof F, Salvador Pena A, Polman CH, Uitdehaag BM. CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis.
J Neuroimmunol. 2003 Jul;140(1-2):188-93.
Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group.
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
Mult Scler. 2003 Aug;9(4):342-8.
Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P.
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.
Arch Neurol. 2003 Aug;60(8):1073-81.
Killestein J, Eikelenboom MJ, Izeboud T, Kalkers NF, Ader HJ, Barkhof F, Van Lier RA, Uitdehaag BM, Polman CH. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
J Neuroimmunol. 2003 Sep;142(1-2):141-8.
Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, Barkhof F.
Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2003 Sep;2(9):555-62.
van Veen T, van Winsen L, Crusius JB, Kalkers NF, Barkhof F, Pena AS, Polman CH, Uitdehaag BM. [Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.
Neurology. 2003 Nov 11;61(9):1245-9.
Hooper-van Veen T, Schrijver HM, Zwiers A, Crusius JB, Knol DL, Kalkers NF, Laine ML, Barkhof F, Pena AS, Polman CH, Uitdehaag BM.
The interleukin-1 gene family in multiple sclerosis susceptibility and disease course.
Mult Scler. 2003 Dec;9(6):535-9.
van Walderveen MA, van Schijndel RA, Pouwels PJ, Polman CH, Barkhof F. Related Articles,
Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis.
J Magn Reson Imaging. 2003 Dec;18(6):656-64.
Bot JC, Barkhof F, Polman CH, Lycklama a Nijeholt GJ, de Groot V, Bergers E, Ader HJ, Castelijns JA. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.
Neurology. 2004 Jan 27;62(2):226-33.
Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Related Articles,
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004 Feb;61(2):217-21.
Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A.
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
Mult Scler. 2004 Feb;10(1):41-6.
Floris S, van der Goes A, Killestein J, Knol DL, Barkhof F, Polman CH, Dijkstra CD, de Vries HE, Meilof JF. Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels.
J Neuroimmunol. 2004 Mar;148(1-2):172-7.
Bo L, Geurts JJ, Ravid R, Barkhof F.
Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis.
Neuropathol Appl Neurobiol. 2004 Apr;30(2):106-17. Review.
Zwemmer JN, van Veen T, van Winsen L, van Kamp GJ, Barkhof F, Polman CH, Uitdehaag BM.
No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler. 2004 Jun;10(3):272-7.
Schrijver HM, Hooper-van Veen T, van Belzen MJ, Crusius JB, Pena AS, Barkhof F, Polman CH, Uitdehaag BM. Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis.
Eur J Immunogenet. 2004 Jun;31(3):133-40.
Van Oosten BW, Barkhof F, Polman CH.
[New diagnostic criteria for multiple sclerosis in clinical practice]
Ned Tijdschr Geneeskd. 2004 Jul 17;148(29):1417-22. Dutch.
Uitdehaag BM, Geurts JJ, Barkhof F, Polman CH.
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee.
Neurology. 2004 Sep 28;63(6):1140; author reply 1140. No abstract available.
Zwemmer J, Uitdehaag B, van Kamp G, Barkhof F, Polman C.
Association of APOE polymorphisms with disease severity in MS is limited to women.
Neurology. 2004 Sep 28;63(6):1139; author reply 1139. No abstract available.
Schrijver HM, Crusius JB, Garcia-Gonzalez MA, Polman CH, Pena AS, Barkhof F, Uitdehaag BM.
Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis.
J Interferon Cytokine Res. 2004 Sep;24(9):536-42.
Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L. Related
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.
J Neuroimmunol. 2004 Oct;155(1-2):155-60.
Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G.
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
Neurology. 2004 Oct 26;63(8):1439-45.
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G. Related Articles,
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
Lancet. 2004 Oct 23-29;364(9444):1489-96.
Lazeron RH, Rombouts SA, Scheltens P, Polman CH, Barkhof F.
An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. Mult Scler. 2004 Oct;10(5):549-55.
Bot JC, Blezer EL, Kamphorst W, Lycklama A Nijeholt GJ, Ader HJ, Castelijns JA, Ig KN, Bergers E, Ravid R, Polman C, Barkhof F.
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology. 2004 Nov;233(2):531-40. Epub 2004 Sep 22
Ropele S, Filippi M, Valsasina P, Korteweg T, Barkhof F, Tofts PS, Samson R, Miller DH, Fazekas F. Assessment and correction of B1-induced errors in magnetization transfer ratio measurements.
Magn Reson Med. 2005 Jan;53(1):134-40.
Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH.
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J Neuroimmunol. 2005 Jan;158(1-2):222-30.
Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. Related Articles,
MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.
Magn Reson Med. 2005 Feb;53(2):256-66.
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Neurology. 2005 Mar 22;64(6):987-91.
Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F.
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
AJNR Am J Neuroradiol. 2005 Mar;26(3):572-7.
Korteweg T, Barkhof F, Uitdehaag BM, Polman CH.
How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. Ann Neurol. 2005 Apr;57(4):606-7. No abstract available.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M.
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005 May;4(5):281-8. Review.
Barkhof F, McKinstry RC.
Quantifying spinal cord demyelination with magnetic transfer imaging.
Neurology. 2005 May 24;64(10):1677-8. No abstract available.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M.
Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005 Jun;4(6):341-8. Review.
Minneboo A, Uitdehaag BM, Ader HJ, Barkhof F, Polman CH, Castelijns JA. Related Articles,
Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
Neurology. 2005 Jul 12;65(1):56-61.
Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Related Articles,
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005 Jul;236(1):254-60.
Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ.
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.
Neurology. 2005 Aug 23;65(4):633-5.
Lazeron RH, Boringa JB, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, Eikelenboom MI, Scheltens PH, Barkhof F, Polman CH.
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.
Mult Scler. 2005 Oct;11(5):524-31.
Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li D, Menzler S, Miller DH, Petkau J, Wolinsky J; Sylvia Lawry Centre for MS Research.
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials.
Neurology. 2005 Nov 8;65(9):1447-54.
Nielsen JM, Korteweg T, Barkhof F, Uitdehaag BM, Polman CH.
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria.
Ann Neurol. 2005 Nov;58(5):781-3.
Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bo L, van der Valk P, Barkhof F, de Vries HE.
Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis. 2005 Dec;20(3):953-60. Epub 2005 Jul 21.
Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS.
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006 Feb;27(2):455-61. No abstract available.
Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ.
MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med. 2006 Mar;55(3):478-83.
Korteweg T, Tintore M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, Fernando K, Filippi M, Agosta F, Rocca M, Fazekas F, Enzinger C, Matthews P, Parry A, Polman C, Montalban X, Barkhof F.
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006 Mar;5(3):221-7.
Vrenken H, Rombouts SA, Pouwels PJ, Barkhof F.
Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. AJNR Am J Neuroradiol. 2006 Apr;27(4):868-74.
Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M.
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr;63(4):614-9. No abstract available
Filippi M, Rocca MA, Arnold DL, Bakshi R, Barkhof F, De Stefano N, Fazekas F, Frohman E, Wolinsky JS. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis.
Eur J Neurol. 2006 Apr;13(4):313-25.
Vrenken H, Pouwels PJ, Geurts JJ, Knol DL, Polman CH, Barkhof F, Castelijns JA.
Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging. 2006 May;23(5):628-36.
Korteweg T, Uitdehaag BM, Knol DL, Smithuis RH, Algra PR, de Vries C, Poppe PA, van Waesberghe JH, Bergers E, Lycklama A Nijeholt GJ, Polman CH, Barkhof F.
Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol. 2006 May 18; [Epub ahead of print]
Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M; Sylvia Lawry Centre for MS Research.
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.
Neurology. 2006 May 9;66(9):1384-9.
Nielsen JM, Barkhof F, van Oosten BW, Polman CH.
The role of spinal cord imaging in the diagnosis of multiple sclerosis.
Nat Clin Pract Neurol. 2006 May;2(5):283-6; quiz 287.
Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology. 2006 Aug 30; ......
Vrenken H, Geurts JJ, Knol DL, van Dijk LN, Dattola V, Jasperse B, van Schijndel RA, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ.
Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 2006 Sep;240(3):811-20. Epub 2006 Jul 25.
Wu Y, Warfield SK, Tan IL, Wells WM 3rd, Meier DS, van Schijndel RA, Barkhof F, Guttmann CR.
Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI.
Neuroimage. 2006 Sep;32(3):1205-15. Epub 2006 Jun 22.
Teunissen CE, Dijkstra CD, Jasperse B, Barkhof F, Vanderstichele H, Vanmechelen E, Polman CH, Bo L. Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis.
Neuropathol Appl Neurobiol. 2006 Jun;32(3):318-31.
Vrenken H, Pouwels PJ, Ropele S, Knol DL, Geurts JJ, Polman CH, Barkhof F, Castelijns JA. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler. 2007 Jul;13(6):708-16.
Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2007 Sep 13
Minneboo A, Jasperse B, Barkhof F, Uitdehaag BM, Knol DL, de Groot V, Polman CH, Castelijns JA. Predicting short-term disability progression in early MS: added value of MRI parameters. J Neurol Neurosurg Psychiatry. 2007 Dec 12
Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; for the BENEFIT investigators**.Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b.J Neurol. 2007 Nov 15;
Jasperse B, Valsasina P, Neacsu V, Knol DL, De Stefano N, Enzinger C, Smith SM, Ropele S, Korteweg T, Giorgio A, Anderson V, Polman CH, Filippi M, Miller DH, Rovaris M, Barkhof F, Vrenken H; Magnetic Imaging in Multiple Sclerosis (MAGNIMS) study group. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.J Magn Reson Imaging. 2007 Oct;26(4):881-5.
Jasperse B, Vrenken H, Sanz-Arigita E, de Groot V, Smith SM, Polman CH, Barkhof F. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage. 2007 Nov 15;38(3):529-37.
van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, Ravid R, Verweij CL, Huitinga I, Polman CH, Uitdehaag BM. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol. 2007 Oct;190(1-2):157-64.
Liedorp M, Sanchez E, van Hoogstraten IM, von Blomberg BM, Barkhof F, Polman CH, Killestein J. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1146-8.
Geurts JJ, Bö L, Roosendaal SD, Hazes T, Daniëls R, Barkhof F, Witter MP, Huitinga I, van der Valk P. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2007 Sep;66(9):819-27.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 Aug 4;370(9585):389-97.
Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, Rovaris M, Thompson AJ, Montalban X, Miller DH.MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007 Aug;6(8):677-86.
Nielsen JM, Moraal B, Polman CH, Poppe P, de Vos M, Freedman MS, Kappos L, Barkhof F, Bauer L, Pohl C, Sandbrink R, Hartung HP, Uitdehaag BM. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. Mult Scler. 2007 Jul;13(6):717-21. Epub 2007 Mar 15.
Jongen PJ, Lycklama a Nijeholt G, Lamers KJ, Doesburg WH, Barkhof F, Lemmens WA, Klasen IS, Hommes OR. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol. 2007;58(2):90-5.
Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, Barkhof F, Polman CH, Teunissen CE. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol. 2007 May;254(5):631-7.
Kalkers NF, Strijers RL, Jasperse MM, Neacsu V, Geurts JJ, Barkhof F, Polman CH, Stam CJ. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clin Neurophysiol. 2007 Jun;118(6):1332-40.
van Winsen LM, Hooper-van Veen T, van Rossum EF, Koper JW, Barkhof F, Polman CH, Uitdehaag BM. Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS. J Neuroimmunol. 2007 May;186(1-2):150-5.
Jasperse B, Minneboo A, de Groot V, Kalkers NF, van Helden PE, Uitdehaag BM, Barkhof F, Polman CH. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol. 2007 Feb;64(2):190-4.
Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH.A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol. 2007 Mar;254(3):306-14.
Lazeron RH, de Sonneville LM, Scheltens P, Polman CH, Barkhof F. Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Mult Scler. 2006 Dec;12(6):760-8.
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007 Jan 25;356(4):371-8.
Bö L, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol. 2007 Jan;64(1):76-80.
Korteweg T, Uitdehaag BM, Knol DL, Smithuis RH, Algra PR, de Vries C, Poppe PA, van Waesberghe JH, Bergers E, Lycklama à Nijeholt GJ, Polman CH, Barkhof F. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol. 2007 Jan;17(1):67-71.
H Vrenken and JJ Geurts. Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. Expert Rev Neurother 2007; 7: 271-279.
Geurts JJ, Blezer EL, Vrenken H, van der Toorn A, Castelijns JA, Polman CH, Pouwels PJ, Bö L, Barkhof F. Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? J Neurol. 2008 Feb;255(2):183-91
Wattjes MP, Harzheim M, Lutterbey GG, Hojati F, Simon B, Schmidt S, Schild HH, Barkhof F. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol. 2008 May 2.
Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology. 2008 Mar 25;70(13 Pt 2):1134-40.
Roosendaal SD, Moraal B, Vrenken H, Castelijns JA, Pouwels PJ, Barkhof F, Geurts JJ .In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging. 2008 Apr;27(4):726-31.
Rocca MA, Agosta F, Sormani MP, Fernando K, Tintorè M, Korteweg T, Tortorella P, Miller DH, Thompson A, Rovira A, Montalban X, Polman C, Barkhof F, Filippi M. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008 Feb 18.
Duan Y, Hildenbrand PG, Sampat MP, Tate DF, Csapo I, Moraal B, Bakshi R, Barkhof F, Meier DS, Guttmann CR. Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Feb;29(2):340-6
Manson SC, Wegner C, Filippi M, Barkhof F, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta F, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Korteweg T, Polman C, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Frank JA, Matthews PM. Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res. 2008 May;187(1):25-31.
Wegner C, Filippi M, Korteweg T, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta F, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Barkhof F, Polman C, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Matthews PM. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol. 2008 Feb;15(2):113-22.
Zwemmer J, Bot J, Jelles B, Barkhof F, Polman Ch.At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. Mult Scler. 2008 Apr;14(3):428-30.
Rovaris M, Judica E, Sastre-Garriga J, Rovira A, Sormani MP, Benedetti B, Korteweg T, De Stefano N, Khaleeli Z, Montalban X, Barkhof F, Miller DH, Polman C, Thompson A, Filippi M. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler. 2008 Jan 21.
Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, Miller D, Montalban X, Thompson A, Yousry T, Tintore M, de Stefano N, Palace J, Rovaris M, Polman C, Fazekas F; MAGNIMS network. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. J Neurol. 2008 Jan;255(1):1-10.
Jasperse B, Valsasina P, Neacsu V, Knol DL, De Stefano N, Enzinger C, Smith SM, Ropele S, Korteweg T, Giorgio A, Anderson V, Polman CH, Filippi M, Miller DH, Rovaris M, Barkhof F, Vrenken H; Magnetic Imaging in Multiple Sclerosis (MAGNIMS) study group. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging. 2007 Oct;26(4):881-5.
V Neacsu, B Jasperse, T Korteweg, DL Knol, P Valsasina, M Filippi, F Barkhof, M Rovaris, and H Vrenken. Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. J Magn Reson Imaging 2008; 28: 559-565.
Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol D, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F, Association between MRI parameters and the MS severity scale: a 12 year follow-up study, Mult Scler. 2009 May;15(5):632-7.
Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ, Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis, Arch Neurol. 2009 May;66(5):601-9.
Roosendaal SD, Moraal B, Pouwels PJ, Vrenken H, Castelijns JA, Barkhof F, Geurts JJ, Accumulation of cortical lesions in MS: relation with cognitive impairment,
Mult Scler. 2009 Jun;15(6):708-14.
Korteweg T, Rovaris M, Neacsu V, Filippi M, Comi G, Uitdehaag BM, Knol DL, Polman CH, Barkhof F, Vrenken H. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. Mult Scler; 2009, vol. 15 (4) pp. 465-471.
Korteweg T, Tintore M, Uitdehaag BM, Knol DL, Vrenken H, Rovira A, Frederiksen J, Miller DH, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enzinger C, Parry A, Polman CH, Montalban X, Barkhof F. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. European radiology; 2009 Sep;19(9): pp. 2244-8.
SE Baranzini, J Wang, RA Gibson, N Galwey, Y Naegelin, F Barkhof, EW Radue, RL Lindberg, BM Uitdehaag, MR Johnson, A Angelakopoulou, L Hall, JC Richardson, RK Prinjha, A Gass, JJ Geurts, J Kragt, M Sombekke, H Vrenken, P Qualley, RR Lincoln, R Gomez, SJ Caillier, MF George, H Mousavi, R Guerrero, DT Okuda, BA Cree, AJ Green, E Waubant, DS Goodin, D Pelletier, PM Matthews, SL Hauser, L Kappos, CH Polman, and JR Oksenberg. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18: 767-778.
B Moraal, DS Meier, PA Poppe, JJ Geurts, H Vrenken, WM Jonker, DL Knol, RA van Schijndel, PJ Pouwels, C Pohl, L Bauer, R Sandbrink, CR Guttmann, and F Barkhof. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009; 250: 506-514.
MH Sombekke, C Lukas, JB Crusius, D Tejedor, J Killestein, D Arteta, A Martinez, BM Uitdehaag, DL Knol, AS Pena, JJ Geurts, PL De Jager, F Barkhof, H Vrenken, and CH Polman. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009; 66: 1531-1536.
MM Vellinga, H Vrenken, HE Hulst, CH Polman, BM Uitdehaag, PJ Pouwels, F Barkhof, and JJ Geurts. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging 2009; 29: 774-779.
MM Vellinga, JJ Geurts, E Rostrup, BM Uitdehaag, CH Polman, F Barkhof, and H Vrenken. Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging 2009; 29: 768-773.
Schoonheim MM, Geurts JJG, Barkhof F. The limits of functional reorganization in multiple sclerosis. NEUROLOGY 2010;74:1246-1247
Roosendaal SD, Hulst HE, Feenstra HEM, Vrenken H, Castelijns JA, Pouwels PJW, Barkhof F, Geurts JJG. Structural and functional hippocampal changes in MS patients with intact memory. Radiology 2010;255(2):595-604.
Roosendaal SD, Schoonheim MM, Hulst HE, Sanz-Arigita EJ, Smith SM, Geurts JJG, Barkhof F. Early adaptation of resting state networks in MS. Brain 2010
H Vrenken, A Seewann, DL Knol, CH Polman, F Barkhof, and JJ Geurts. Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types. AJNR Am J Neuroradiol 2010 Mar;31(3):541-8. Epub 2009 Oct 22